



---

### Tacrolimus 0.03% Ophthalmic Oil Emulsion

Version number: 1.0

Volume: 50mL

---

Tacrolimus 10mg/mL Stock Solution	1.5mL
Sorbitan Monooleate 0.2% Olive Oil Stock Solution	q.s. 50mL

---

This compound should be prepared in an ISO Class 5 environment by a licensed pharmacist or supervised pharmacy technician trained in proper aseptic technique. Review USP <797> and check with your state board(s) of pharmacy to ensure proper compliance with regulations on the preparation of CSPs. Personnel assessments, sterility, potency and endotoxin levels testing should be outlined in the pharmacy SOPs.

#### SUGGESTED COMPOUNDING PROCEDURES

1. Within an ISO Class 5 air quality environment, aseptically transfer Sorbitan Monooleate 0.2% Stock Solution to Tacrolimus 10mg/mL Stock Solution and bring to final volume. Mixture will be cloudy liquid.
2. Aseptically transfer step 1 into appropriate sterile, single use containers. Provide frequent mixing/shaking when dividing step 1.
3. Suggested Quality Assessments – follow pharmacy SOPs:
  - a. Sterility
  - b. Label - auxiliary labels, storage, BUD, **SHAKE WELL**, compounded medication

Note: According to USP Chapter <797>, in the absence of passing a sterility test the storage periods for compounded sterile preparations (high risk) cannot exceed the following time periods:

Controlled Room Temperature: not more than 24 hours

Cold Temperature: not more than 3 days

Refer to USP chapter <797>.

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, intended duration of therapy, formulation from commercially available

products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

**Beyond-Use Date is estimated to be 90 days.**

### **Precautions**

Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a primary engineering control (PEC) that meets USP Chapter <800> standards. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

02/18rd